PACE-B: Phase 3 trial of SBRT in localised prostate cancer

874 patients randomised to SBRT (5 fractions) or moderate hypofactionation or conventional fractionation (20 or 39 fractions). SBRT demonstrated non-inferiority for biochemical or clinical failure, reducing treatment from 4 weeks to 1–2 weeks with no increase in late toxicity.

Why it matters: This is the largest randomised trial confirming SBRT as a standard of care. With The Raypilot System's continuous motion tracking, margins can be tightened further, supporting the move from selected cases to routine practice.